WSO - February 2024 - 152

152
International Journal of Stroke 19(2)
Table 1. (Continued)
VII. Blinding/Sham/Control
Blinding approach and rationale (single, double, triple)
Blinding success exploration (e.g. questionnaires)
Sham usage and rationale
If sham is used, its description
Active control usage and rationale
If an active control is used, its description
VIII, Side effects and negative findings
Adverse events and tolerability monitored (e.g. by a questionnaire)
Report negative findings
IX. Clinical specific; Patient characteristics
Patient Demographics (age, sex, ethnicity)
Lesion characteristics (including lesion location, and size) supported by imaging, if applicable
Comorbidities
Clinical deficits and their dynamics
General therapeutic procedures
Pharmacological treatments at the time of stimulation
X. Preclinical specific
Species, age, sex, weight
Rationale for the species used
Lesion model, localization, extension, time elapsed from lesion to stimulation
Rationale on inclusion or not of behavioral outcome measures
Rationale on inclusion or not of follow-up to recovery
TMS: transcranial magnetic stimulation; MEP: motor evoked potential.
Recommendation 3
Knowledge gap 4: clinically relevant
preclinical animal models
(a) Preclinical studies should:
(i) conduct complete outcome assessments across
cellular-molecular, physiological and behavioral
domains, and;
(ii) include standardized behavioral outcomes common
to human studies
(b) Clinical studies/trials should:
(i) use standardized assessments with established
psychometric properties, and;
(ii) report the minimal clinically important difference
for outcomes that align with
ICF categories and/or study hypotheses.
International Journal of Stroke, 19(2)
The next gap emerging from the survey was the need for
preclinical models with increased clinical relevance. The
main translational barriers were a lack of (1) measures to
test interactions between the effects of NIBS on the brain
and behavior; (2) studies that directly align NIBS stimulation
parameters with those commonly used in humans and
that closely replicate the effects that commonly used protocols
for humans have on the brain (e.g. considering brain
size and/or cortical architecture); (3) studies that test NIBS
effects according to lesion characteristics (i.e. lesion location
and size); and (4) animal models with comorbidities

WSO - February 2024

Table of Contents for the Digital Edition of WSO - February 2024

Contents
WSO - February 2024 - Cover1
WSO - February 2024 - Cover2
WSO - February 2024 - 127
WSO - February 2024 - Contents
WSO - February 2024 - 129
WSO - February 2024 - 130
WSO - February 2024 - 131
WSO - February 2024 - 132
WSO - February 2024 - 133
WSO - February 2024 - 134
WSO - February 2024 - 135
WSO - February 2024 - 136
WSO - February 2024 - 137
WSO - February 2024 - 138
WSO - February 2024 - 139
WSO - February 2024 - 140
WSO - February 2024 - 141
WSO - February 2024 - 142
WSO - February 2024 - 143
WSO - February 2024 - 144
WSO - February 2024 - 145
WSO - February 2024 - 146
WSO - February 2024 - 147
WSO - February 2024 - 148
WSO - February 2024 - 149
WSO - February 2024 - 150
WSO - February 2024 - 151
WSO - February 2024 - 152
WSO - February 2024 - 153
WSO - February 2024 - 154
WSO - February 2024 - 155
WSO - February 2024 - 156
WSO - February 2024 - 157
WSO - February 2024 - 158
WSO - February 2024 - 159
WSO - February 2024 - 160
WSO - February 2024 - 161
WSO - February 2024 - 162
WSO - February 2024 - 163
WSO - February 2024 - 164
WSO - February 2024 - 165
WSO - February 2024 - 166
WSO - February 2024 - 167
WSO - February 2024 - 168
WSO - February 2024 - 169
WSO - February 2024 - 170
WSO - February 2024 - 171
WSO - February 2024 - 172
WSO - February 2024 - 173
WSO - February 2024 - 174
WSO - February 2024 - 175
WSO - February 2024 - 176
WSO - February 2024 - 177
WSO - February 2024 - 178
WSO - February 2024 - 179
WSO - February 2024 - 180
WSO - February 2024 - 181
WSO - February 2024 - 182
WSO - February 2024 - 183
WSO - February 2024 - 184
WSO - February 2024 - 185
WSO - February 2024 - 186
WSO - February 2024 - 187
WSO - February 2024 - 188
WSO - February 2024 - 189
WSO - February 2024 - 190
WSO - February 2024 - 191
WSO - February 2024 - 192
WSO - February 2024 - 193
WSO - February 2024 - 194
WSO - February 2024 - 195
WSO - February 2024 - 196
WSO - February 2024 - 197
WSO - February 2024 - 198
WSO - February 2024 - 199
WSO - February 2024 - 200
WSO - February 2024 - 201
WSO - February 2024 - 202
WSO - February 2024 - 203
WSO - February 2024 - 204
WSO - February 2024 - 205
WSO - February 2024 - 206
WSO - February 2024 - 207
WSO - February 2024 - 208
WSO - February 2024 - 209
WSO - February 2024 - 210
WSO - February 2024 - 211
WSO - February 2024 - 212
WSO - February 2024 - 213
WSO - February 2024 - 214
WSO - February 2024 - 215
WSO - February 2024 - 216
WSO - February 2024 - 217
WSO - February 2024 - 218
WSO - February 2024 - 219
WSO - February 2024 - 220
WSO - February 2024 - 221
WSO - February 2024 - 222
WSO - February 2024 - 223
WSO - February 2024 - 224
WSO - February 2024 - 225
WSO - February 2024 - 226
WSO - February 2024 - 227
WSO - February 2024 - 228
WSO - February 2024 - 229
WSO - February 2024 - 230
WSO - February 2024 - 231
WSO - February 2024 - 232
WSO - February 2024 - 233
WSO - February 2024 - 234
WSO - February 2024 - 235
WSO - February 2024 - 236
WSO - February 2024 - 237
WSO - February 2024 - 238
WSO - February 2024 - 239
WSO - February 2024 - 240
WSO - February 2024 - 241
WSO - February 2024 - 242
WSO - February 2024 - 243
WSO - February 2024 - 244
WSO - February 2024 - Cover3
WSO - February 2024 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com